DOCSLIB.ORG

00010-2020.Supp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
00010-2020.Supp APPENDIX A: PubMed search history, conducted in April 2019 "Carcinoma, Non-Small-Cell Lung/surgery"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/radiotherapy"[Mesh] OR (("Carcinoma, Non- Small-Cell Lung"[Mesh] OR "Non-Small-Cell Lung Carcinoma"[Title/abstract] OR "Non-Small-Cell Lung Carcinomas"[Title/abstract] OR "Non-Small-Cell Lung cancer"[Title/abstract] OR "Non-Small-Cell Lung cancers"[Title/abstract] OR NSCLC[title/abstract]) AND (Surgery[Title/abstract] OR surgeries[Title/abstract] OR surgical[Title/abstract] OR operation[Title/abstract] OR operations[Title/abstract] OR operative[Title/abstract] OR Radiotherapy[Title/abstract] OR Radiotherapies[Title/abstract] OR "Radiation Therapy"[Title/abstract] OR "Radiation Therapies"[Title/abstract] OR "Radiation Treatment"[Title/abstract] OR "Radiation Treatments"[Title/abstract] OR radiochemotherapy[title/abstract] OR radiosurgery[title/abstract])) AND ((stage[title/abstract] AND III[title/abstract]) OR "stage IIIa"[title/abstract] OR "stage IIIb"[title/abstract] OR "stage IIIc"[title/abstract] OR advanced[title/abstract]) AND (random*[title/abstract] OR "Controlled Clinical Trial"[ptyp] OR "Randomized Controlled Trial"[ptyp] OR "Clinical Trial, Phase III"[ptyp]) AND ("1987/01/01"[PDAT] : "3000/12/31"[PDAT]) APPENDIX B: Included studies and their respective treatment arms Table 1: Overview of the included studies Public Reporting N = Treatment regimen per study arm Phase 2 Random- Funding Geo- Toxicity Mean ation system or 3 isation grap as end- follow- studies hy point up [mo] Burkes et al 1992 ECOG 42 ChT+S+ChT - - - p2 - unknown NA x RChT+S+RC Strauss et al 1992 Not specified 45 hT - - - p2 R* publ NA x 53 Crinò et al 1993 Not specified 61 RChT RT - - n/a R* unknown EU - Kubota et al 1994 Not specified 63 ChT+RT ChT - - n/a R* publ Asia - Pujol et al 1994 WHO criteria 33 ChT+S+RT ChT+RT - - p2 R* publ EU x 16 Rosell et al 1994 Not specified 60 ChT+S S - - n/a R* priv EU x Roth et al 1994 CTCAE v.1 60 ChT+S S - - n/a R* unknown NA - Wagner et al 1994 Not specified 57 ChT+S RT+S - - p2 R* publ NA x Darwish et al 1995 WHO criteria 46 ChT+S+/-RT - - - p2 R* unknown EU - glob Jeremic et al 1996 RTOG 131 RT RChT - - n/a R* unknown al - CTCAE unknown v + Tannehill et al 1997 RTOG/EORTC 26 RChT1 RChT2 - - p2 R* publ NA x Bonner JA 1998 CTCAE v.1 99 RT RT RChT - p3 R* publ NA - Isokangas et al 1998 WHO criteria 27 ChT+RChT - - - n/a - priv EU x 19 glob Jeremic et al 1998 RTOG/EORTC 47 RChT - - - p2 R* unknown al - Furuse et al 1999 WHO/EORTC 314 RChT RT+ RChT - - p3 R* publ Asia x 60 Ichinose et al 1999 JCOG criteria 17 RChT - - - n/a - unknown Asia - 24 Felip et al 2000 WHO criteria 83 ChT1+S ChT2+S - - n/a R* unknown EU x 19 Segawa et al 2000 WHO criteria 50 RChT - - - p2 R* unknown Asia x 41 Takamori et al 2000 WHO criteria 22 RChT+S - - - n/a - unknown Asia x Ulutin et al 2000 RTOG 45 RT RChT1 RChT2 - n/a - unknown Asia - 16 glob Jeremic et al 2001 RTOG/EORTC 195 RChT1 RChT2 - - p2 R* publ al x Elias et al 2002 Not specified 50 RT+S+RT ChT+S+ChT - - n/a R* unknown NA - CTCAE Johnstone et al 2002 unknown v 73 ChT+S+ChT CHt+RT+ChT ChT - p3 R* unknown NA x 48 Kim et al 2002 WHO criteria 89 RChT RT - - p3 R* priv Asia - Pergolizzi et al 2002 WHO criteria 40 RT - - - p2 R* unknown EU x Cappuzzo et al 2003 CTCAE v.2 129 RChT - - - n/a R* unknown EU x CTCAE unknown v + Leong et al 2003 RTOG 60 ChT1+RChT ChT2+RChT - - n/a R* priv Asia x 14 Nagai et al 2003 JCOG criteria 62 ChT+S S - - p3 R* publ Asia - 74.4 CTCAE Schild et al 2003 unknown v 234 RChT1 RChT2 - - p3 R* publ NA - 43 WHO criteria + Ulutin et al 2003 RTOG/EORTC 51 RChT RT - - n/a R* unknown Asia - 14 Cakir et al 2004 WHO criteria 176 RT RChT - - p3 R* unknown Asia - QLQ Schumacher et Symptome ChT+RChT+ al 2004 scale 54 S ChT+S+RT - - p3 R* unknown EU - ChT1(+S)+R Sculier et al 2004 WHO criteria 351 T ChT2(+S)+RT - - p3 R* unknown EU x 47.7 ChT+RChT+ Semik et al 2004 Not specified 273 S ChT+S+RT - - p3 R* publ EU x Zatloukal et al 2004 WHO criteria 102 concRChT seqRChT - - n/a R* publ EU x 39 Atagi et al 2005 CTCAE v.2 46 RT RChT - - p3 R* publ Asia x CTCAE unknown v + RChT+ Belani et al 2005 RTOG 256 ChT1+RChT ChT2+RChT ChT - p2 R* priv NA x 39.6 Belani et al 2005 CTCAE v.2 119 ChT+RT1 ChT+RT2 - - p3 R* publ NA x Beslija et al 2005 WHO criteria 60 ChT+RT RT - - p2 R* unknown EU - Choy et al 2005 CTCAE 51 ChT+RT+Me - - - p2 - priv NA x 36.7 unknown v di Van Schil et al 2005 CTCAE v.3 308 IndCht+RT IndChT+S - - n/a R* priv EU x 70 Gouda et al 2006 RTOG 60 ChT+RChT RChT RT - n/a R* unknown EU x Misirlioglu et al 2006 Not specified 66 RT +Vitamin RT - - n/a R* unknown Asia - ChT+RT Scagliotti et al 2006 CTCAE v.2 89 ChT+RChT - - n/a R* priv EU - Yokomise et al 2006 RTOG 41 RChT1+S RChT2+S - - n/a R* unknown Asia - Esteban et al 2007 WHO criteria 154 ChT1+S/RT ChT2+S/RT - - n/a R* unknown EU x 36 Hamouda et al 2007 WHO criteria 66 ChT+ RT RT - - n/a R* unknown EU x 15 Patel et al 2007 RTOG/EORTC 35 ChT+RChT - - - p2 - priv NA - 45 Perry et al 2007 Not specified 37 (S)+ChT (S)ChT+RT - - p3 R* publ NA - Tawfik et al 2007 CTCAE v.2 27 ChT+RChT - - - p2 - unknown EU x Vokes et al 2007 Not specified 331 RChT ChT+RChT - - n/a R* priv NA x 38 Yang et al 2007 RTOG 55 ChT+RT1 ChT+RT2 - - n/a R* unknown Asia x Hanna et al 2008 CTCAE v.3 147 RChT+ChT RChT - - p3 R* priv NA x 41.6 CTCAE v.3 + Hughes et al 2008 RTOG 12 ChT+RT/IT - - - n/a - publ EU x 10 RChT+ChT1 Kelly et al 2008 CTCAE v.2 543 +ChT2 RChT+ChT1 - - p3 R* priv NA - 27 CTCAE v.3 + ChT+ Nyman et al 2008 RTOG 151 ChT+RChT1 ChT+RChT2 RChT3 - n/a R* priv EU x 52 Socinski et al 2008 CTCAE v.2 68 ChT1+RChT ChT2+RChT - - p2 R* publ NA - 44 Stinchcombe et al 2008 CTCAE v.2 23 ChT+RChT - - - n/a - priv NA x 30 CTCAE Stupp et al 2008 unknown v 46 RchT+S - - - p2 - priv EU x 58 Berghmans et al 2009 CTCAE v.2 49 RChT+CT CT+RChT - - p3 R* priv EU - 51 Garrido et al 2009 CTCAE v.2 139 RChT+ChT ChT+RChT - - p2 R* priv EU - 57 Harada et al 2009 CTCAE v.3 59 RChT1 RChT2 - - n/a - unknown Asia - 30 Friedel et al 2010 Not specified 120 RchT+S - - - p2 - unknown Asia - Girard et al 2010 CTCAE v.3 + 46 ChT+S RChT1+S RChT2+ - p2 R* priv EU x 31.4 Lent Soma S (Fra) (late) Hallqvist et al 2010 CTCAE v.3 75 ChT+RChT - - - p3 - priv EU x 39 Lu et al 2010 CTCAE v.2 379 ChT+RChT ChT+RChT - - p3 R* publ NA x 44.4 glob Movsas et al 2010 CTCAE v.2 64 RChT+ChT1 RChT+ChT2 - - p2 R* priv al - 41.5 Nawrocki et al 2010 CTCAE v.2 99 RT RChT - - p2 R* priv EU x 41 CTCAE v.2 + Pöttgen et al 2010 RTOG/EORTC 28 RChT - - - n/a R* publ EU - 42 Segawa et al 2010 CTCAE v.2 200 RChT1 RChT2 - - p3 R* unknown Asia - glob Senan et al 2010 CTCAE v.3 70 ChT+RChT RChT+ChT - - p2 R* priv al x 14.3 Sun et al 2010 WHO criteria 60 ChT+S ChT+TCM+S - - n/a R* unknown Asia - Takeda et al 2010 JCOG criteria 68 ChT+RChT - - - p2 - publ Asia - Xu et al 2010 CTCAE v.3 21 RChT - - - p2 - unknown Asia x 15 Govindan et al 2011 CTCAE v.3 101 RChT1 RChT - - p2 R* publ NA - 32 2012/ CTCAE v.2 + Atagi et al 2018 RTOG/EORTC 200 RChT RT - - p3 R* publ Asia x 19.4 ChT+RT+Ch Carter et al 2012 CTCAE v.2 119 T ChT+RT - - p3 R* priv NA - 36 ChT+RT+Ch Hoang et al 2012 CTCAE v.2 119 T ChT+RT - - p3 R* priv NA - 36 Katakami et al 2012 CTCAE v.2 58 IndChT+S RChT+S - - p3 R* publ Asia x 60.7 Wang et al 2012 CTCAE v.2 65 RChT1 RChT2 - - p2 R* publ Asia - 46 CTCAE v.3 + Chen et al 2013 RTOG 99 ChT+RT1 ChT+RT2 - - n/a R* unknown Asia - 33.6 CTCAE v.3 + Choy et al 2013 RTOG (late) 98 RChT1 RChT2 - - n/a R* priv NA x ChT+RChT Eberhardt et al 2013 Not specified 64 +/- S - - - p2 R* priv EU x 107 CTCAE v.3 + Kaira et al 2013 RTOG 41 RChT+/-ChT - - - p2 - unknown Asia x 15.1 Oh et al 2013 CTCAE v.3 93 RChT1 RChT2 RChT3 - p3 R* publ Asia x Sugawara et al 2013 CTCAE v.3 70 RChT1 RChT2 - - p2 R* unknown Asia x RChT + Aggarwal et al 2014 Not specified 249 RChT RChT + S S - n/a - unknown NA - Akopov et al 2014 Not specified 42 ChT+S PDT+ChT+S - - n/a R* unknown Asia - Arrieta et al 2014 CTCAE v.3 35 RChT+NO - - - n/a - unknown NA x 18.9 Debus et al 2014 Not specified 385 RChT RChT+Epo - - p3 R* priv EU - Maguire et al 2014 CTCAE v.3 130 RChT ChT+RT - - p2 R* publ EU x 35.2 Shen et al 2014 CTCAE v.3 140 S+RChT S+ChT - - n/a R* unknown Asia x van den Heuvel et al 2014 CTCAE v.3 102 RChT RChT+IT - - p2 R* priv EU - 29 Ahn et al 2015 CTCAE v.3 420 RChT RChT+ChT - - p3 R* priv Asia x 50.7 RChT1+ RChT+ Cetuxi- Cetuxi- Bradley et al 2015 CTCAE v.3 544 RChT1 RChT2 mab mab p2 R* priv NA - 21.2 Crvenkova et al 2015 RTOG/EORTC 85 RChT1 RChT2 - - n/a R* unknown EU - Eberhardt et al 2015 CTCAE v.3 161 RChT+Boost RChT+S - - p3 R* priv EU - 78 CTCAE v.2 + RTOG + Lent Fournel et al 2015 Soma 127 ChT+RChT RChT+ChT - - p2 R* priv EU x 17.7 Pless et al 2015 CTCAE v.1 232 ChT+RT+S ChT+S - - n/a R* priv EU x MWA+R- Xu et al 2015 Not specified 98 (Ch)T R-(Ch)T - - n/a R* unknown Asia x 24 Yao et al 2015 CTCAE v.3 40 RChT RChT+S1 - - n/a R* publ Asia - WHO criterai + Zhu et al 2015 RTOG/EORTC 63 RChT+Tx RChT - - n/a R* unknown Asia x WHO criteria + glob Ardizzoni et al 2016 EORTC/RTOG 151 ChT+RT ChT+RChT - - p3 R* priv al x 73.2 Feng et al 2016 CTCAE v.3 72 RChT+S1 RChT - - n/a R* unknown Asia x Kong et al 2016 CTCAE v.4 49 RT +/- ChT1 RT +/-ChT2 - - n/a - publ Asia x 21.4 Lin et al 2016 CTCAE v.3 130 ChT1+RChT ChT2+RChT - - p3 R* publ Asia x glob Senan et al 2016 CTCAE v.3 598 RChT1 RChT2 - - p3 R* priv al - 22.4 Sun et al 2016 CTCAE v.3 19 RChT+/-ChT - - - p2 - publ Asia x Zhao et al 2016 Not specified 60 RChT+TCM RChT - - n/a R* unknown Asia - Zhao et al 2016 CTCAE v.3 100 RChT1 RChT2 - - p3
Load more

Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • UCSD Moores Cancer Center Neuro-Oncology Program
    UCSD Moores Cancer Center Neuro-Oncology Program Recent Progress in Brain Tumors 6DQWRVK.HVDUL0'3K' 'LUHFWRU1HXUR2QFRORJ\ 3URIHVVRURI1HXURVFLHQFHV 0RRUHV&DQFHU&HQWHU 8QLYHUVLW\RI&DOLIRUQLD6DQ'LHJR “Brain Cancer for Life” Juvenile Pilocytic Astrocytoma Metastatic Brain Cancer Glioblastoma Multiforme Glioblastoma Multiforme Desmoplastic Infantile Ganglioglioma Desmoplastic Variant Astrocytoma Medulloblastoma Atypical Teratoid Rhabdoid Tumor Diffuse Intrinsic Pontine Glioma -Mutational analysis, microarray expression, epigenetic phenomenology -Age-specific biology of brain cancer -Is there an overlap? ? Neuroimmunology ? Stem cell hypothesis Courtesy of Dr. John Crawford Late Effects Long term effect of chemotherapy and radiation on neurocognition Risks of secondary malignancy secondary to chemotherapy and/or radiation Neurovascular long term effects: stroke, moya moya Courtesy of Dr. John Crawford Importance Increase in aging population with increased incidence of cancer Patients with cancer living longer and developing neurologic disorders due to nervous system relapse or toxicity from treatments Overview Introduction Clinical Presentation Primary Brain Tumors Metastatic Brain Tumors Leptomeningeal Metastases Primary CNS Lymphoma Paraneoplastic Syndromes Classification of Brain Tumors Tumors of Neuroepithelial Tissue Glial tumors (astrocytic, oligodendroglial, mixed) Neuronal and mixed neuronal-glial tumors Neuroblastic tumors Pineal parenchymal tumors Embryonal tumors Tumors of Peripheral Nerves Shwannoma Neurofibroma
    [Show full text]
  • 5 Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation
    Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation 67 5 Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation G-One Ahn and J. Martin Brown CONTENTS 5.1 Targeting Tumor Hypoxia 5.1 Targeting Tumor Hypoxia 67 5.2 Oxygen-Level Enhancers 68 5.3 Hypoxia-Selective Radiosensitizers 69 Tumor hypoxia was first postulated from histo- 5.3.1 Nitroimidazoles 69 logical studies of human lung adenocarcinomas by 5.3.2 Mixed-Function Radiosensitizers 69 Thomlinson and Gray (1955). They reasoned that, 5.3.3 DNA-Affinic Radiosensitizers 71 because of unrestrained growth, tumor cells are 5.3.4 Limitations of HSR 71 forced away from blood vessels beyond the effec- 5.4 Hypoxic Cytotoxins 72 5.4.1 Introduction 72 tive diffusion distance of oxygen (O2) in respiring 5.4.2 Combination of Hypoxic Cytotoxins with Ionizing tissues, hence becoming hypoxic and eventually Radiation 72 necrotic (Fig. 5.1a). Given the typical values for 5.4.3 Nitroimidazoles 73 intracapillary O2 tensions and consumption rates, 5.4.4 Other Nitroaromatics 73 they calculated that O diffusion distances would 5.4.4.1 CB 1954 73 2 be approximately 150 Pm and this was consistent 5.4.4.2 SN 23862 and PR-104 74 Thomlinson 5.4.4.3 RSU 1069 and RB 6145 74 with their histological observations ( 5.4.5 Quinones 75 and Gray 1955). This type of hypoxia has come to be 5.4.5.1 Mitomycin C 75 termed “chronic,” or “diffusion-limited,” hypoxia. 5.4.5.2 Porfiromycin 75 Acute hypoxia also develops in tumors through 5.4.5.3 EO9 75 temporal (reversible) cessation or reduction of 5.4.6 Benzotriene di-N-Oxides 76 5.4.7 Tertiary Amine N-Oxides 78 tumor blood flow resulting from highly disorga- 5.4.7.1 Nitracrine N-Oxides 78 nized tumor vasculature (Fig.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Oxygen Effect in the Development of Radiosensitizers
    Translational Oncology Volume 4 Number 4 August 2011 pp. 189–198 189 www.transonc.com Six Degrees of Separation: Bryan T. Oronsky*, Susan J. Knox† and Jan Scicinski* The Oxygen Effect *RadioRx, Inc, Mountain View, CA, USA; †Department in the Development of Radiation Oncology, Stanford University Medical of Radiosensitizers Center, Stanford, CA, USA Abstract The popular theory six degrees of separation is used in this review as an analogy to relate all radiosensitization to oxygen. As the prime mover of all radiosensitizers, the pervasive influence of oxygen has consciously or uncon- sciously influenced the direction of research and development and provided the benchmark against which all other compounds and approaches are measured. It is the aim of this review to develop the six degrees of separation from oxygen analogy as a unifying framework for conceptually organizing the field and for giving context to its varied subspecializations and theories. Under such a framework, it would become possible for one area to consider ques- tions and problems found in other areas of radiosensitization, using a common analogy, that would allow for further development and unification of this multifaceted discipline. In this review, approaches to the development of radio- sensitizers and the current state of research in this field are discussed, including promising new agents in various stages of clinical development. Translational Oncology (2011) 4, 189–198 Introduction support metabolic pathways. The ability of more aggressive cancer The view that everything is connected to everything else according to cells to survive hypoxic conditions leads to selection against apoptosis the popular six degrees of separation theory finds corroboration on a and an increased resistance to chemotherapy, as well as a propensity therapeutic level in the field of radiosensitization.
    [Show full text]
  • Repeated Tumor Oximetry to Identify Therapeutic Window During Metronomic Cyclophosphamide Treatment of 9L Gliomas
    ONCOLOGY REPORTS 26: 281-286, 2011 Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas SRIRAM MUPPARAJU1,2, HUAGANG HOU1,2, JEAN P. LARIVIERE1, HAROLD SwaRTZ1,2, YOUSSEF JOUNAIDI3 and NADEEM KHAN1,2 1EPR Center for Viable Systems, Dartmouth Medical School, Hanover, NH 03755; 2Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756; 3Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA 02215, USA Received February 1, 2011; Accepted March 17, 2011 DOI: 10.3892/or.2011.1268 Abstract. Malignant gliomas are aggressive and angiogenic Introduction tumors with high VEGF content. Consequently, approaches such as metronomic chemotherapy, which have an anti- Gliomas are highly angiogenic tumors with rapid infiltrative angiogenic effect, are being investigated. However, a lack of growth and profound microvascular proliferation (1). Despite an appropriate technique that can facilitate the identification improvements in surgery and radiotherapy; the prognosis of vascular changes during antiangiogenic treatments has of glioma patients has remained poor (2,3). Consequently, restricted therapeutic optimization. We have investigated the new methods are urgently needed to improve and synergize potential of tumor pO2 as a marker to detect vascular changes strategies for the treatment of gliomas. The presence of tumor during metronomic chemotherapy. Electron paramagnetic hypoxia (pO2 <10-15 mmHg) further compromises the outcome resonance (EPR) oximetry was used to repeatedly assess tumor by stimulating glioma progression, aggressive phenotypes, pO2 during metronomic cyclophosphamide treatment of subcu- metastases and resistance to therapies (4-6). Tumor hypoxia taneous 9L tumors. The 9L tumors were hypoxic with a pO2 of cannot be predicted by tumor type or size and therefore must 5.6-8 mmHg and a tumor volume of 247-300 mm3 prior to any be measured.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Orphan Drug Designation List
    Orphan Drug Designations and Approvals List as of 09‐01‐2015 Governs October 1, 2015 ‐ December 31, 2015 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 (‐)‐(3aR,4S,7aR)‐4‐Hydroxy‐4‐ m‐tolylethynyl‐octahydro‐ Novartis indole‐1‐carboxylic acid Pharmaceuticals methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. 2 (1‐methyl‐2‐nitro‐1H‐ imidazole‐5‐yl)methyl N,N'‐ bis(2‐broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono 3 (1‐methyl‐2‐nitro‐1H‐ imidazole‐5‐yl)methyl N,N'‐ bis(2‐bromoethyl) Threshold diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. 4 (1OR)‐7‐amino‐12‐fluoro‐ 2,10,16‐trimethyl‐15 oxo‐ 10,15,16,17‐tetrahydro‐2H‐8,4‐ Treatment of anaplastic (metheno)pyrazolo[4,3‐ lymphoma kinase (ALK)‐positive h][2,5,11]benzoxadiazacyclote or ROS1‐positive non‐small cell tradecine‐3‐carbonitrile n/a 6/23/2015 lung cancer Pfizer, Inc. 5 (1R,3R,4R,5S)‐3‐O‐[2‐O‐ Treatment of vaso‐occlusive benzoyl‐3‐O‐(sodium(2S)‐3‐ crisis in patients with sickle cell cyclohexyl‐propanoate‐ n/a 2/17/2009 disease. Pfizer, Inc. 6 (1S)‐1‐(9‐deazahypoxanthin‐9‐ yl)‐1,4‐dideoxy‐1,4‐imino‐D‐ Treatment of acute Mundipharma ribitol‐hydrochloride n/a 8/13/2004 lymphoblastic leukemia Research Limited Page 1 of 359 Orphan Drug Designations and Approvals List as of 09‐01‐2015 Governs October 1, 2015 ‐ December 31, 2015 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 7 Treatment of chronic lymphocytic leukemia and related leukemias to include (1S)‐1‐(9‐deazahypoxanthin‐9‐ prolymphocytic leukemia, adult T‐ yl)‐1,4‐dideoxy‐1,4‐imino‐D‐ cell leukemia, and hairy cell Mundipharma ribitol‐hydrochloride n/a 8/10/2004 leukemia Research Ltd.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]